Carbylan Therapeutics Schedules Third Quarter 2015 Financial Results

PALO ALTO, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ: CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced that the Company will issue financial results for the third quarter of 2015 on Wednesday, November 11, 2015, prior to the market open. Following the announcement, a conference call will be held at 8:30 a.m. ET to discuss the results.

The conference call can be accessed by dialing (866) 430-0334 for domestic callers, and (704) 908-0407 for international callers. The conference ID number is 61222119. In addition to the call, a live webcast of the event will be available on the investor relations page of the Company's website at www.carbylan.com.

Following the call, the event will remain archived on the Carbylan website for one year. In addition to the archive, a recording of the call will be available until November 18, 2015. The recording can be accessed by dialing (855) 859-2056 for domestic callers, and (404) 537-3406 for international callers. The conference ID number for the recording is 61222119.

About Carbylan Therapeutics

Carbylan is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel and proprietary combination therapies that address significant unmet clinical needs. The Company's lead product candidate, Hydros-TA, is a proprietary, cross-linked combination of low dose corticosteroid and novel hyaluronic acid viscosupplement, designed to provide both rapid and sustained osteoarthritis pain relief via a single intra-articular injection.

CONTACT: The Ruth Group
         David Burke/Lee Roth
         646-536-7009/7012
         [email protected]/[email protected]

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Advance Auto Parts falls on revenue miss, weak guidance
• China semiconductor equipment imports grow 9% in July, Barclays comments